Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sjoerd Rijpkema is active.

Publication


Featured researches published by Sjoerd Rijpkema.


Clinical and Vaccine Immunology | 2009

Kinetics of the Natural, Humoral Immune Response to Salmonella enterica Serovar Typhi in Kathmandu, Nepal

Anoop S. Pulickal; Samir C. Gautam; Elizabeth A. Clutterbuck; Stephen Thorson; Buddha Basynat; Neelam Adhikari; Katherine Makepeace; Sjoerd Rijpkema; Ray Borrow; Jeremy Farrar; Andrew J. Pollard

ABSTRACT Typhoid fever is a major public health problem in developing countries, conservatively estimated to occur in 17 million cases and be responsible for 200,000 deaths annually. We investigated the acquisition of natural immunity to Salmonella enterica serovar Typhi in a region where typhoid is endemic by testing sera from an age-stratified sample of 210 healthy participants in Kathmandu, Nepal, for bactericidal activity toward S. Typhi and for anti-Vi capsular polysaccharide antibodies. Bactericidal titers in children were significantly lower than those in newborns and adults (P < 0.0001). Anti-S. Typhi bactericidal geometric mean titers were age dependent, increasing 10-fold during childhood. Anti-Vi polysaccharide antibody geometric mean concentrations were also lower in children than in adults. Data presented here indicate the possibility of a relationship between low levels of bactericidal activity toward S. Typhi in serum and susceptibility to disease, as observed for other polysaccharide-encapsulated bacteria. Bactericidal antibody may be a marker of protective immunity against S. Typhi.


Fems Immunology and Medical Microbiology | 2003

Differences in immunogenicity and protection in mice and guinea pigs following intranasal immunization with Helicobacter pylori outer membrane antigens

Jacqueline I. Keenan; Sjoerd Rijpkema; Zarmina Durrani; Justin A. Roake

Mice and guinea pigs were intranasally immunized with either recombinant lipoprotein 20 or Helicobacter pylori outer membrane vesicles (OMV). Cholera toxin was used as mucosal adjuvant. In mice, both vaccines elicited systemic and local IgG responses, which correlated with significantly lower levels of H. pylori colonization. In contrast, only OMV proved immunogenic in guinea pigs, with the development of both systemic and local immune responses. These antibodies did not, however, correlate with protection in these animals, which suggests that vaccine formulation is as important as choice of antigen in the development of an H. pylori vaccine.


Journal of Clinical Microbiology | 2004

Evaluation of a Candidate International Standard Preparation for Human Anti-Toxoplasma Immunoglobulin G

Peter Rigsby; Sjoerd Rijpkema; Edward Guy; Janet Francis; Rose Gaines Das

ABSTRACT A freeze-dried human serum preparation containing immunoglobulin G (IgG) to Toxoplasma gondii was assessed for its suitability as an international reference reagent in an international collaborative study by 24 laboratories from 17 countries. This candidate standard was compared with the third international standard (IS) for human anti-Toxoplasma serum, TOXM, with the previous second IS, TOXS, and with a range of other serum samples. Samples were tested with the Sabin-Feldman dye test and a range of agglutination assays and enzyme immunoassays. This study emphasizes the need for appropriate standards if intermethod agreement of estimates is to be achieved. On the basis of the results of this study, the preparation was established by the World Health Organization as the first IS for human anti-Toxoplasma IgG, with an assigned potency of 20 IU per ampoule of total anti-Toxoplasma antibodies.


Fems Immunology and Medical Microbiology | 2003

Investigation of the biological relevance of Helicobacter pylori cagE locus diversity, presence of CagA tyrosine phosphorylation motifs and vacuolating cytotoxin genotype on IL-8 induction in gastric epithelial cells

Robert J. Owen; Sally Sharp; Andrew J. Lawson; Zarmina Durrani; Sjoerd Rijpkema; Mark Kidd

Isolates of Helicobacter pylori from dyspeptic patients in England and South Africa were tested for ability to induce interleukin-8 (IL-8) in gastric cells. All isolates were cagA-positive, which was used as a marker for the presence of the cag pathogenicity island. The aims were to determine if activities were related to diversity within cagE (HP0544), a locus encoding a key component in the Type IV secretion system, and if disease severity might be linked to a combination of strain features. We found that isolates were heterogeneous in ability to induce IL-8 activity with the 23 positive isolates (59%) showing activities ranging from 260 to 3200 pg ml(-1). The cagE locus was detected in most isolates and RFLP analysis of a 1.52-kb internal fragment showed interstrain diversity with 12 combined (MboI/NlaIII) types. Most cagE genotypes were not associated with IL-8 induction, however two genotypes were found only in IL-8-inducing strains and one genotype was associated with lack of IL-8 induction. IL-8 activity was not associated with either the number or composition of cagA tyrosine phosphorylation motifs and vacA m-type. Although we found a weak association between cagE type and the ability to induce IL-8, our results imply that gastric cell factors or bacterial factors other than vacA, cagA and cagE are involved in the induction of IL-8 and the development of severe gastric disease.


Expert Review of Vaccines | 2007

New adjuvants: EU regulatory developments

Dorothea Sesardic; Sjoerd Rijpkema; Brijesh Prakash Patel

This paper discusses EU regulatory texts that are relevant for the introduction of new adjuvants in human vaccines and discusses the EU requirements at the developmental level, during the manufacturing process and at the final product stage. The emphasis is on regulatory expectations regarding safety at preclinical and clinical stages. The article highlights regulatory concerns and existing bottlenecks that have led to a slow approval process for new adjuvants.


Journal of Clinical Microbiology | 2003

Identification of cagA Tyrosine Phosphorylation DNA Motifs in Helicobacter pylori Isolates from Peptic Ulcer Patients by Novel PCR-Restriction Fragment Length Polymorphism and Real-Time Fluorescence PCR Assays

Robert J. Owen; Sally Sharp; Stephanie A. Chisholm; Sjoerd Rijpkema

ABSTRACT Cag pathogenicity island-containing Helicobacter pylori (type I) induces signal transduction pathways resulting in tyrosine phosphorylation of proteins adjacent to the site of bacterial adhesion on host gastric epithelial cells. Conventional block PCR-restriction fragment length polymorphism (RFLP) and real-time LightCycler (LC) PCR hybridization assays, validated by direct sequencing, were designed to test for the presence of three nucleotide sequences corresponding to tyrosine phosphorylation motifs (TPMs) A, B, and C in 84 isolates of H. pylori type I from patients in England. Overall, the PCR assays demonstrated that one or more TPMs were present in 62 strains (75%). Motif A was common (71% of strains), whereas motifs B and C were rarer (8% of strains). Strains lacking a TPM were typically vacuolating cytotoxin genotype vacA m2. Motif A was widely distributed in relation to disease severity and was more commonly (but not significantly [P = 0.071]) associated with gastric ulcer than with duodenal ulcer (86 versus 56%). The LC hybridization assay provided a rapid means of detecting all three motifs, but RFLP analysis was more specific for TPM-A. TPMs provide novel additional strain markers for defining cagA variation, including identification of RFLP types within TPM-A. The presence of a particular TPM was not of direct diagnostic value, either singly or in combination, but the higher proportion of TPM-A strains in gastric ulcer patients merits further investigation.


Human Vaccines | 2005

Investigation in a Model System of the Effects of Combinations of Anthrax and Pertussis Vaccines Administered to Service Personnel in the 1991Gulf War

Sjoerd Rijpkema; Trudy Adams; Peter Rigsby; Dorothy Xing; Michael J. Corbel

The toxicity and immunogenicity of the anthrax and pertussis vaccine combinations used in the 1991 Gulf War was assessed in NIH, A/J and Balb/c mice. Inoculation of pertussis vaccines, vaccine combinations, or aluminium salt caused illness, splenomegaly and significant weight loss. Although some animals recovered eventually, a lethal form of ascites developed in some NIH mice and body weights of A/J and Balb/c mice remained below normal levels. Inoculation of anthrax vaccine produced little effect. Exposure to diluted vaccine combinations produced less serious side effects of shorter duration. Single vaccinations induced specific IgG1 antibodies whereas a mixture of IgG1 and IgG2a was produced after multiple injections. Antigen stimulation of spleen cells from mice exposed to pertussis vaccines induced high levels of NO and IL-6, whereas stimulated spleen cells from mice exposed to anthrax vaccine produced only low levels of IL-6. In mice, pertussis vaccines act as an adjuvant for anthrax vaccine, but these vaccines are also the major cause of toxicity of the vaccine combination. The relatively high vaccine dose used, together with the low sensitivity of mice to anthrax toxin, emphasises that caution should be exercised in applying these results to human recipients of these vaccines.


Biochemical and Biophysical Research Communications | 2008

Anthrax lethal toxin suppresses chemokine production in human neutrophil NB-4 cells

Helen V. Barson; Hans J. Mollenkopf; Stefan H. E. Kaufmann; Sjoerd Rijpkema

Microarray analysis was used to investigate the effects of Bacillus anthracis lethal toxin (LT) on human neutrophil-like NB-4 cells to identify markers of intoxication. Genes down-regulated after a 2h LT exposure included those encoding chemokines and transcription factors. Significant decreases in the mRNA of interleukin-8, CCL20, CCL3 and CCL4, which are important chemoattractants for immune cells, were observed using real-time PCR (12.3, 4.0, 4.1 and 2.2-fold (p<0.05), respectively). The decreases were more pronounced at 4 and 8h and were LT-specific. Decreases in chemokine protein levels were evident after 24h and were sensitive to low concentrations of LT. Co-incubation with an anti-lethal factor mAb at 500 and 250ng/ml restored levels of interleukin-8 to 100% and 50%, respectively. The results reveal that LT suppresses the cellular immune response and that this assay is a useful tool for the analysis of toxin-neutralising antibody activity in a biologically relevant system.


Fems Immunology and Medical Microbiology | 2003

Orogastric vaccination of guinea pigs with Helicobacter pylori sonicate and a high dose of cholera toxin lowers the burden of infection

Zarmina Durrani; Sjoerd Rijpkema

Guinea pigs were vaccinated orogastrically with Helicobacter pylori cell sonicate (CS) and 10 microg or 100 microg cholera toxin (CT) or CT only. Nai;ve animals were used as a control. In both experiments, vaccination primed the local IgG and IgA response, irrespective of the CT dose. After challenge, only the group of animals immunised with CS and 100 microg CT had a significantly lower number of H. pylori in the antral region of the stomach, but vaccination did not prevent H. pylori infection. This protective effect was not associated with a switch in IgG subclass, which remained predominantly IgG2. The levels of specific antibodies in serum and the gastric mucosa which were similar to naive unprotected animals. In conclusion, the ability of mucosal adjuvants such as CT to induce a protective immune response may be host dependent and findings in the Helicobacter-mouse model should be interpreted with caution.


Human Vaccines | 2006

A Fluorescent Peptide Substrate for Measuring the ADP-Ribosylation Activity of the Cholera Toxin A-Subunit

Chun-Ting Yuen; Sjoerd Rijpkema

Vibrio cholerae serogroups O1 and O139 Bengal produce cholera toxin (CT) a typical AB5 bacterial toxin comprising an ADP-ribosylation enzyme A-subunit (CTA) and a carbohydrate binding B-subunit (CTB). DUKORALR the inactivated oral cholera vaccine has recently been licensed for use in the European Union. This vaccine contains killed whole cells of V. cholerae and 1 mg of purified recombinant CTB (rCTB). DUKORALR has a good safety profile and there has been no indication that active CT is present. Nevertheless, an assay that confirms the absence of active CTA in the vaccine is advantageous to ensure vaccine safety. Conventional assays such as the Y-cell assay can not detect biologically active amounts of CT in DUKORALR because of the large amount of rCTB present. We have developed an assay based on a fluorescently labelled 11-mer peptide substrate that detects CTA activity despite the presence of excess rCTB.

Collaboration


Dive into the Sjoerd Rijpkema's collaboration.

Top Co-Authors

Avatar

Zarmina Durrani

National Institute for Biological Standards and Control

View shared research outputs
Top Co-Authors

Avatar

Peter Rigsby

University of Hertfordshire

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gail Whiting

National Institute for Biological Standards and Control

View shared research outputs
Top Co-Authors

Avatar

Jason Hockley

National Institute for Biological Standards and Control

View shared research outputs
Top Co-Authors

Avatar

Robert J. Owen

Public health laboratory

View shared research outputs
Top Co-Authors

Avatar

Trudy Adams

National Institute for Biological Standards and Control

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge